RT Journal Article
SR Electronic
T1 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
JF Breathe
JO Breathe
FD European Respiratory Society
SP 200086
DO 10.1183/20734735.0086-2020
VO 16
IS 3
A1 Christopher J. Brereton
A1 Helen E. Jo
YR 2020
UL http://breathe.ersjournals.com/content/16/3/200086.abstract
AB An acute exacerbation of idiopathic pulmonary fibrosis (AEIPF) is a potentially fatal complication of an already debilitating disease. Management is currently centred on delivering excellent supportive care and identifying reversible triggers. Despite growing international awareness and collaboration, no effective therapies have been identified. Corticosteroids are often the mainstay of treatment; however, the evidence base for their use is poor. Here, we review our current understanding of the disease process and how to manage it, with a focus on the role of corticosteroid therapy.Acute exacerbations of IPF cause a rapid deterioration in respiratory status and are challenging to manage. With few other options, corticosteroids are widely used as standard of care; however. the evidence to support this is poor. https://bit.ly/3gvSokN